港股異動丨康希諾生物(6185.HK)高開11% 國內首個新冠疫苗專利獲批
格隆匯8月17日丨康希諾生物(6185.HK)高開11%,報214港元,總市值529億港元;康希諾(688185.SH)競價階段則漲近7%。據國家知識產權局消息,由軍科院軍事醫學研究院陳薇院士團隊及康希諾生物聯合申報的新冠疫苗(Ad5-nCoV疫苗)專利申請已被授予專利權,這是我國首個新冠疫苗專利。該專利於今年3月18日申請,8月11日授權。康希諾與軍科院生物工程研究所的合作由來已久,公司上市的第一個疫苗產品,埃博拉病毒疫苗Ad5-EBOV就是由康希諾與軍科院生物工程研究所合作研發完成,此次合作已是雙方第二次合作。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.